Actualités Biophytis - ALBPS | Actions Euronext

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth...

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the...

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study...

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a...

Biophytis Announces Publication of its 2018 Annual Report

Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual...

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a...

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical...

Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Re...

PARIS, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biophytis (ALBPS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ALBPS Actualités

Biophytis to Restate Previously Issued Financial Statements

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

Biophytis Announces Publication of its 2018 Annual Report

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Re...

Biophytis: statut de médicament orphelin pour Sarconeos

Biophytis: dans le vert sur un relèvement d'analyste.

Biophytis: conclusion d'accords pour une levée de fonds.

Biophytis: feu vert de la FDA pour l'étude SARA-INT.

Biophytis: demande d'IND auprès de la FDA.

Biophytis: nomination d'un directeur business development.

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biophytis (ALBPS) Actualités

Biophytis (ALBPS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

ALBPS Actualités

Biophytis to Restate Previously Issued Financial Statements

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

Biophytis Announces Publication of its 2018 Annual Report

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Re...

Biophytis: statut de médicament orphelin pour Sarconeos

Biophytis: dans le vert sur un relèvement d'analyste.

Biophytis: conclusion d'accords pour une levée de fonds.

Biophytis: feu vert de la FDA pour l'étude SARA-INT.

Biophytis: demande d'IND auprès de la FDA.

Biophytis: nomination d'un directeur business development.

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités